CA2107669C - Preparation for treating wounds and hemorrhoides - Google Patents

Preparation for treating wounds and hemorrhoides Download PDF

Info

Publication number
CA2107669C
CA2107669C CA002107669A CA2107669A CA2107669C CA 2107669 C CA2107669 C CA 2107669C CA 002107669 A CA002107669 A CA 002107669A CA 2107669 A CA2107669 A CA 2107669A CA 2107669 C CA2107669 C CA 2107669C
Authority
CA
Canada
Prior art keywords
beraprost
preparation
salts
active ingredient
preparation according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002107669A
Other languages
English (en)
French (fr)
Other versions
CA2107669A1 (en
Inventor
Makoto Okumura
Toshiaki Okuda
Tsutomu Nakamura
Motoyuki Yajima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Kaken Pharmaceutical Co Ltd
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaken Pharmaceutical Co Ltd, Toray Industries Inc filed Critical Kaken Pharmaceutical Co Ltd
Publication of CA2107669A1 publication Critical patent/CA2107669A1/en
Application granted granted Critical
Publication of CA2107669C publication Critical patent/CA2107669C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Furan Compounds (AREA)
  • Medicinal Preparation (AREA)
CA002107669A 1992-02-07 1993-02-05 Preparation for treating wounds and hemorrhoides Expired - Fee Related CA2107669C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2280892 1992-02-07
JPH4-22808 1992-02-07
JPH4-189867 1992-06-24
JP18986792 1992-06-24
PCT/JP1993/000151 WO1993015739A1 (fr) 1992-02-07 1993-02-05 Remede destine aux blessures ou aux hemorroides

Publications (2)

Publication Number Publication Date
CA2107669A1 CA2107669A1 (en) 1993-08-08
CA2107669C true CA2107669C (en) 2004-06-01

Family

ID=26360087

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002107669A Expired - Fee Related CA2107669C (en) 1992-02-07 1993-02-05 Preparation for treating wounds and hemorrhoides

Country Status (8)

Country Link
US (3) US5403867A (enExample)
EP (1) EP0583482B1 (enExample)
JP (1) JP3209427B2 (enExample)
AT (1) ATE188119T1 (enExample)
CA (1) CA2107669C (enExample)
DE (1) DE69327432T2 (enExample)
TW (1) TW234691B (enExample)
WO (1) WO1993015739A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5266571A (en) * 1992-01-09 1993-11-30 Amer Moh Samir Treatment of hemorrhoids with 5-HT2 antagonists
JP3209427B2 (ja) * 1992-02-07 2001-09-17 科研製薬株式会社 創傷または痔疾治療剤
EP0731712A4 (en) * 1993-10-29 2005-11-09 Univ Boston PHYSIOLOGICALLY STABLE COMPOSITIONS OF BUTYRIC ACID, SALTS AND BUTYRIC ACID DERIVATIVES AS ANTINEOPLASTIC AGENTS
US6190691B1 (en) 1994-04-12 2001-02-20 Adolor Corporation Methods for treating inflammatory conditions
US5962477A (en) * 1994-04-12 1999-10-05 Adolor Corporation Screening methods for cytokine inhibitors
IT1269634B (it) * 1994-05-06 1997-04-08 Indena Spa Medicamento topico ad attivita' cicatrizzante
CA2191601A1 (en) * 1994-06-02 1995-12-14 Hirofumi Tanabe Pharmaceutical composition for treating peripheral circulation disorder
PT742011E (pt) * 1994-11-17 2002-10-31 Toray Industries Preparacao que pode ser absorvida por via percutanea
CA2188931C (en) * 1995-02-27 2007-09-11 Reiji Kasukawa Agent for treating cor pulmonale
US6573282B1 (en) 1995-09-12 2003-06-03 Adolor Corporation Peripherally active anti-hyperalgesic opiates
US5849761A (en) * 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
US6017963A (en) 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US5869059A (en) * 1996-01-16 1999-02-09 Mon's Tea Partnership Herbal composition for hemorrhoid treatment
AU774861B2 (en) * 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
US6365198B1 (en) * 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
US20040266880A1 (en) * 2002-02-22 2004-12-30 Fumie Sato Antipruritics
ES2309380T3 (es) * 2002-08-09 2008-12-16 Taisho Pharmaceutical Co., Ltd Agente antipruritico.
US7737182B2 (en) * 2002-08-09 2010-06-15 Taisho Pharmaceutical Co., Ltd. Pharmaceuticals for xerosis
MXPA05010552A (es) 2003-04-02 2005-11-23 Nexmed Holdings Inc Composiciones de prostaglandina y su uso para el tratamiento de vasoespasmos.
JP4157889B2 (ja) * 2003-06-25 2008-10-01 有限会社 循環器研究所 性交機能改善用外用製剤
GB0524103D0 (en) * 2005-11-26 2006-01-04 Medical Res Council Healing
WO2010105112A1 (en) * 2009-03-11 2010-09-16 Hemaquest Pharmaceuticals, Inc. Detection of short-chain fatty acids in biological samples
WO2011038224A1 (en) 2009-09-24 2011-03-31 Trustees Of Boston University Methods for treating viral disorders
US8618068B2 (en) 2009-12-08 2013-12-31 Trustees Of Boston University Methods and low dose regimens for treating red blood cell disorders
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
JP2014510156A (ja) 2011-04-07 2014-04-24 ネクスメッド ホールディングス，インコーポレイテッド レイノー病を治療する方法および組成物
WO2014164886A1 (en) * 2013-03-13 2014-10-09 Allergan, Inc. Prostanoid receptor agonist compounds and their use
CN109715173A (zh) 2016-07-15 2019-05-03 维拉克塔治疗公司 供基于nk细胞的疗法使用的hdac抑制剂
CN114206447A (zh) 2019-05-31 2022-03-18 维拉克塔附属公司 用组蛋白脱乙酰基酶抑制剂治疗病毒相关的癌症的方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK142235B (da) * 1974-12-20 1980-09-29 Yamanouchi Pharma Co Ltd Analogifremgangsmåde til fremstilling af 20-alkoxy-16-methyl-prostadiensyre-derivater.
US4025645A (en) * 1976-01-27 1977-05-24 Jelenko Iii Carl Non-steroid topical agent for alleviating inflammation in mammals
GB1595056A (en) * 1976-10-12 1981-08-05 Wellcome Found Pharmaceutical combination
JPS5391110A (en) * 1977-01-20 1978-08-10 Yamanouchi Pharmaceut Co Ltd Novel drug composition for rectal infusion
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
DE3162659D1 (en) * 1980-07-22 1984-04-19 Ono Pharmaceutical Co 9,11-methano-13-aza-11a-carbathrombanoic acid analogues and pharmaceutical use thereof
DE3631169A1 (de) * 1986-09-11 1988-03-24 Schering Ag Prostacyclinderivate enthaltende mittel fuer die topische anwendung
DE3886936T2 (de) * 1987-10-16 1994-04-28 Toray Industries 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
JPH0311017A (ja) * 1989-06-06 1991-01-18 Green Cross Corp:The プロスタグランジンｅ↓１含有薬剤組成物
ES2093774T3 (es) * 1991-03-14 1997-01-01 R Tech Ueno Ltd Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina.
JP3209427B2 (ja) * 1992-02-07 2001-09-17 科研製薬株式会社 創傷または痔疾治療剤
AU669783B2 (en) * 1993-02-03 1996-06-20 Teijin Limited Dermatologic preparation composition containing prostacyclinas active ingredient

Also Published As

Publication number Publication date
EP0583482A4 (en) 1995-05-03
TW234691B (enExample) 1994-11-21
DE69327432D1 (de) 2000-02-03
JP3209427B2 (ja) 2001-09-17
US5852050A (en) 1998-12-22
CA2107669A1 (en) 1993-08-08
EP0583482B1 (en) 1999-12-29
US5403867A (en) 1995-04-04
DE69327432T2 (de) 2000-05-18
WO1993015739A1 (fr) 1993-08-19
ATE188119T1 (de) 2000-01-15
EP0583482A1 (en) 1994-02-23
US5679707A (en) 1997-10-21

Similar Documents

Publication Publication Date Title
CA2107669C (en) Preparation for treating wounds and hemorrhoides
JPWO1993015739A1 (ja) 創傷または痔疾治療剤
Halebian et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids
US5476664A (en) Treatment of warts using anthralins and occlusion
EP0980245B1 (en) Use of misoprostol or/and misoprostol acid for the treatment of erectile dysfunction
CN115300508A (zh) 包含孟鲁司特与贻贝粘附蛋白的组合的局部制剂
WO2007123867A2 (en) Stable solutions of prostaglandin and uses of same
US5489576A (en) Therapeutic agent for hemorrhoidal diseases
JP2003527430A (ja) １５−ケトプロスタグランジンまたはその誘導体を含むアポトーシス抑制剤
JP2025506988A (ja) 外用トラネキサム酸組成物及びその使用方法
WO2003063879A1 (en) Remedies for glaucoma comprising bunazosin and prostaglandins
WO2022218136A1 (zh) 腺嘌呤作为制备治疗糖尿病溃疡药物的应用
US4400378A (en) Pharmaceutical composition for the treatment of glaucoma
KR0174763B1 (ko) 창상 또는 치질 치료제
JPS5810517A (ja) 非ステロイド系消炎剤を主成分とする点眼剤
Wingerup et al. A new prostaglandin E2-gel for pretreatment of the cervix in nulliparous patients having a late first trimester termination of pregnancy
US20240415794A1 (en) Topical tranexamic acid compositions and methods of use thereof
Rath et al. Preoperative cervical priming by intracervical application of a new sulprostone gel
Perry et al. Uterine trauma associated with midtrimester abortion induced by intra-amniotic prostaglandin F2α with and without concomitant use of oxytocin
Siddall-allum et al. Treatment of secondary postpartum haemorrhage with intramyometrial prostaglandin F2α
Ranjan et al. Evaluation of sulprostone for second trimester abortions and its effects on liver and kidney functions
Raman et al. Intrarectal gemeprost in the treatment of intractable postpartum haemorrhage due to uterine atony
CA2447883A1 (en) Use of nf-kappa-b inhibitors to treat dry eye disorders
Ledward et al. Stimulating uterine activity
JPH0812577A (ja) 外傷性脳損傷防御剤

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed